[1]下肢动脉硬化闭塞症诊治指南[J]. 中华普通外科学文献(电子版), 2016, 10(1): 1-18.
[2]Tsai PS, Lin DC, Jan YT, et al. Lowerextremity muscle wasting in patients with peripheral arterial disease: quantitative measurement and evaluation with CT[J]. Eur Radiol, 2023, 33(6): 4063-4072.
[3]CruzJentoft AJ, Sayer AA. Sarcopenia[J]. Lancet, 2019, 393(10191): 2636-2646.
[4]Cevei M, Onofrei RR, Cioara F, et al. Correlations between the quality of life domains and clinical variables in sarcopenic osteoporotic postmenopausal women[J]. J Clin Med, 2020, 9(2): 441.
[5]Shafiee G, Keshtkar A, Soltani A, et al. Prevalence of sarcopenia in the world: a systematic review and metaanalysis of general population studies[J]. J Diabetes Metab Disord, 2017, 16: 21.
[6]Pizzimenti M, Meyer A, Charles AL, et al. Sarcopenia and peripheral arterial disease: a systematic review[J]. J Cachexia Sarcopenia Muscle, 2020, 11(4): 866-886.
[7]Matsubara Y, Matsumoto T, Inoue K, et al. Sarcopenia is a risk factor for cardiovascular events experienced by patients with critical limb ischemia[J]. J Vasc Surg, 2017, 65(5): 1390-1397.
[8]Sugai T, Watanabe T, Otaki Y, et al. Decreased psoas muscle computed tomography value predicts poor outcome in peripheral artery disease[J]. Circ J, 2018, 82(12): 3069-3075.
[9]郦俊生, 宋云霄, 程捷. 治疗前PLR、NLR和LMR在预测前列腺癌预后中的价值[J]. 检验医学, 2021, 36(6): 631-636.
[10]余建洪, 刘钰. 自贡地区成人外周血SII、NLR、dNLR、 PLR及LMR参考区间的建立[J]. 检验医学, 2019, 34(7): 630-632.
[11]Liu YY, Ruan GT, Ge YZ, et al. Systemic inflammation with sarcopenia predicts survival in patients with gastric cancer[J]. J Cancer Res Clin Oncol, 2023, 149(3): 1249-1259.
[12]Hu Q, Mao W, Wu T, et al. High neutrophiltolymphocyte ratio and platelettolymphocyte ratio are associated with sarcopenia risk in hospitalized renal cell carcinoma patients[J]. Front Oncol, 2021, 11: 736640.
[13]CruzJentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48(1): 16-31.
[14]Seluk N, Albeyogˇlu ??塁, Bastopcu M, et al. Sarcopenia is a risk factor for major adverse cardiac events after surgical revascularization for critical limb ischemia[J]. Vascular, 2023, 31(1): 64-71.
[15]Pizzimenti M, Charles AL, Riou M, et al. Usefulness of platelettolymphocyte ratio as a marker of sarcopenia for critical limb threatening ischemia[J]. Ann Vasc Surg, 2021, 72: 72-78.
[16]Volpato S, Bianchi L, Cherubini A, et al. Prevalence and clinical correlates of sarcopenia in communitydwelling older people: application of the EWGSOP definition and diagnostic algorithm[J]. J Gerontol A Biol Sci Med Sci, 2014, 69(4): 438-446.
[17]Rolland Y, Czerwinski S, Abellan Van Kan G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives[J]. J Nutr Health Aging, 2008, 12(7): 433-450.
[18]Beaudart C, Rizzoli R, Bruyère O, et al. Sarcopenia: burden and challenges for public health[J]. Arch Public Health, 2014, 72(1): 45.
[19]Matsubara Y, Matsumoto T, Aoyagi Y, et al. Sarcopenia is a prognostic factor for overall survival in patients with critical limb ischemia[J]. J Vasc Surg, 2015, 61(4): 945-950.
[20]Zamboni M, Mazzali G, Fantin F, et al. Sarcopenic obesity: a new category of obesity in the elderly[J]. Nutr Metab Cardiovasc Dis, 2008, 18(5): 388-395.
[21]Choi KM. Sarcopenia and sarcopenic obesity[J]. Korean J Intern Med, 2016, 31(6): 1054-1060.
[22]王亚洲, 刘慧玲. 血流感染患者血小板参数的变化[J]. 检验医学, 2021, 36(5): 514-516.
[23]邹小红, 凌利芬, 刘小晴, 等. NLR和SII在不同类型血流感染中的诊断价值[J]. 检验医学与临床, 2021, 18(17): 2501-2503.
[24]乔建兵, 戴宏宇, 徐春华, 等. 炎症因子评分对晚期非小细胞肺癌患者预后评估的应用价值[J]. 江苏大学学报(医学版), 2019, 29(5): 430-435.
[25]Okugawa Y, Toiyama Y, Yamamoto A, et al. Close relationship between immunological/inflammatory markers and myopenia and myosteatosis in patients with colorectal cancer: a propensity score matching analysis[J]. JPEN J Parenter Enteral Nutr, 2019, 43(4): 508-515.[
|